14% of covered lives...

...have preferred formulary access to Merck's Keytruda, which was granted accelerated approval by the FDA for the treatment of advanced cervical cancer in June. Keytruda is the first PD-1 inhibitor approved to treat cervical cancer.

SOURCE: MMIT Analytics, as of June 14, 2018